Wang Ze, Shang Haihua, Li Yazhuo, Zhang Chen, Dong Yan, Cui Tao, Zhang Hongbing, Ci Xiaoyan, Yi Xiulin, Zhang Tiejun, Yan Fengying, Zhang Yaping, Huang Xing, Wu Weidang, Liu Changxiao
Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
Biotechnology Center, Tianjin Institute of Pharmaceutical Research Co. Ltd., Tianjin 300193, China.
Acta Pharm Sin B. 2020 Sep;10(9):1646-1657. doi: 10.1016/j.apsb.2020.05.012. Epub 2020 Jun 27.
Various medicinal ingredients with different tastes are combined according to the theory of compatibility in Chinese materia medica to achieve a better efficacy, while the mechanism was not very clear. Here, the authors studied the interaction between ingredients and human transporters such as the kidney transporters OAT1 and OAT3, the liver transporters OATP1B1 and OATP1B3, and the intestine transporter OATP2B1 to discern the compatibility mechanism of ingredients with different tastes in the Yuanhuzhitong preparation (YHP) comprising (CYH) and (AD), which could relieve pain by restraining the central system. The results show that tetrahydropalmatine (TDE), the major component of CYH, could be transported by OAT3 into kidney, OATP1B1 and OATP1B3 into liver, while imperatorin (IPT) and isoimperatorin (ISP), the two key components of AD, and AD extract showed strong inhibition to OAT1 and OAT3. What's more, AD extract also exerted strongly inhibition to human transporters OATP1B1 and OATP1B3. It was also detected that IPT, ISP, and AD extract significantly downregulated the expression of , , and of liver in mice. The results show that the concentration of TDE in liver and kidney significantly decreased, while the TDE concentration in blood and brain were both significantly enhanced in the presence of IPT, ISP, and AD extract. These results suggest that the ingredients in AD with pungent taste could enhance the exposure of TDE in blood and brain by inhibiting the uptake of TDE in liver and kidney. That is to say, TDE with bitter taste could "flood up" into the central nervous system to play its therapeutic effect by the cut-off of that into liver and kidney in the presence of ingredients within AD. This paper not only proves the meridian distribution of CYH in liver and kidney with the role of OAT3, OATP1B1, and OATP1B3, but also illustrates how to improve the efficacy of CYH by reasonable compatibility with AD. This study may offer a valuable clue to illustrate the mechanism of compatibility theory.
根据中药配伍理论,将各种不同性味的药用成分组合在一起,以达到更好的疗效,但其作用机制尚不完全清楚。在此,作者研究了元胡止痛制剂(YHP)中各成分与人体转运体之间的相互作用,该制剂由醋延胡索(CYH)和白芷(AD)组成,可通过抑制中枢系统来缓解疼痛。研究的人体转运体包括肾脏转运体OAT1和OAT3、肝脏转运体OATP1B1和OATP1B3以及肠道转运体OATP2B1,以阐明YHP中不同性味成分的配伍机制。结果表明,CYH的主要成分延胡索乙素(TDE)可被OAT3转运至肾脏,被OATP1B1和OATP1B3转运至肝脏,而AD的两个关键成分欧前胡素(IPT)和异欧前胡素(ISP)以及AD提取物对OAT1和OAT3表现出强烈抑制作用。此外,AD提取物对人体转运体OATP1B1和OATP1B3也有强烈抑制作用。还检测到IPT、ISP和AD提取物显著下调小鼠肝脏中Oatp1b1、Oatp1b3和Mrp2的表达。结果显示,在存在IPT、ISP和AD提取物的情况下,肝脏和肾脏中TDE的浓度显著降低,而血液和脑中TDE的浓度均显著升高。这些结果表明,AD中具有辛味的成分可通过抑制肝脏和肾脏对TDE的摄取来提高TDE在血液和脑中的暴露量。也就是说,在存在AD内成分的情况下,具有苦味的TDE可通过切断其进入肝脏和肾脏的途径而“涌”入中枢神经系统发挥其治疗作用。本文不仅证明了CYH在肝脏和肾脏中的经络分布以及OAT3、OATP1B1和OATP1B3的作用,还阐明了通过与AD合理配伍提高CYH疗效的方式。该研究可能为阐明配伍理论机制提供有价值的线索。